Business & Finance⟩Finance

Stemline Therapeutics Files for NASDAQ IPO

Disclaimer Please note that we are not authorised to provide any investment advice. The information on this page should be construed for information purposes only. We may earn commissions from the products mentioned on this site.
author imageAlan Draper Last updated:

Stemline Therapeutics is planning to raise $50 mn in an IPO. The biotech company is planning to list on NASDAQ and trade under the symbol STML. The lead underwriters are Oppenheimer & Co and JMP Securities.

Click here for FREE email alerts from Inside IPO >>

Source: Renaissance Capital

Photo: bfishadow via Flickr

  This article was written for Business 2 Community by Alan Draper.
Learn how to publish your content on B2C

Join our Telegram channel to stay up to date on breaking news coverage

author image

Author: Alan Draper

Based in the United Kingdom, Business 2 Community editor Alan is part of the team that’s responsible for ensuring all the content on our site is accurate, relevant and up-to-date. In addition to editing, he is also a writer and an expert on the stock market. Alan has previously written …

View full profile ›

More by this author:

Popular Topics

  Comments on this article are closed.

Get weekly insider business guides & reviews for free

Join our FREE Telegram Group Now!